Skip to Content

Lead Discovery and Biotesting

The lead discovery and biotesting group designs, validates, implements and optimizes robust state-of-the-art biochemical, biophysical, and cell-based assays for novel cancer drug targets to guide medicinal chemistry efforts through the drug discovery process to clinical candidate nomination. These assays identify active chemical or biological entities, characterize them with respect to potency and selectivity and determine their mode of action.

Our lead discovery scientists have extensive experience with diverse target classes using a wide range of assay technologies and make extensive use of automation to streamline their workflow to ensure consistency of data. By generating highly reproducible, quantitative data in a timely manner, project team members enable rapid iterative lead optimization at IACS.

The lead discovery and biotesting team is led by Mary Geck Do, Ph.D.

Newsletter

MD Anderson Hightlights

External Media Coverage

Join our Team

Contact Us

Institute for Applied Cancer Science
MD Anderson Cancer Center
1901 East Road
Houston TX 77054
Tel: 713-745-2600

For questions concerning collaborations or partnerships, please contact:

Eric Devroe
Executive Director of Strategic Alliances
EJDevroe@mdanderson.org

We need your help

Philanthropic support will provide IACS several critical advantages that will ultimately benefit cancer patients by providing them with novel treatments in a shorter timeframe. If you’re interested in advancing this transformative venture, please donate through the myGiving site.


© 2013 The University of Texas MD Anderson Cancer Center